Objectives: Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer. Tissue factor and activated factor VII (FVIIa) complex may contribute to tumor invasiveness by promoting cell migration and angiogenesis. The study objective was to evaluate safety, pharmacokinetics, and efficacy of PCI-27483, a selective FVIIa inhibitor.
Introduction
Tissue factor (TF) is a transmembrane receptor constitutively expressed by fibroblasts surrounding blood vessels [1] . When the endothelium is breached by injury or tissue damage, TF is exposed to its ligand, protease factor VII (FVII), in circulation. The resulting activated FVII (FVIIa) forms a complex with TF (TF:FVIIa), triggering the blood coagulation cascade [2, 3] . Many tumor types express TF, with increased expression correlating with tumor invasiveness and worsened prognosis [4] [5] [6] . moting cell migration through upregulation of chemokines such as interleukin-8 and by inducing angiogenesis through vascular endothelial growth factor signaling [7, 8] . High TF expression correlates with increased venous thromboembolism (VTE) in patients with pancreatic cancer [9] . Patients with cancer have a four-fold greater risk for VTE than the general population, and chemotherapy increases this risk [10] . VTE is associated with advanced cancer stage and poor prognosis [11] .
PCI-27483 is a selective, small-molecule FVIIa inhibitor developed to treat TF-overexpressing cancers. PCI-27483 (90 mg/kg b.i.d.) inhibited tumor growth in mice implanted with cancer cells [12, 13] . Previously, studies of prophylactic anticoagulation with low-molecularweight heparin in advanced pancreatic cancer (APC) have demonstrated a decrease in VTEs but no impact on survival [14, 15] . The first-in-human study of PCI-27483 in healthy adults aimed to determine a pharmacologically effective, single, subcutaneous (SC) dose of PCI-27483 resulting in a cohort mean peak international normalized ratio (INR) ≥2.0 or peak INR ≥3.0 for any subject. With single-dose (≤2.0 mg/kg) PCI-27483, adverse events (AEs) were mild and not treatment related, and no clinically significant laboratory values changed from baseline. Coagulation parameters (including INR) exhibited dosedependent increases [unpubl. data] . Based on these initial results, we report data from a phase 2 study of PCI-27483 in patients with APC.
Methods

Study Design
This open-label, phase 2 trial (NCT01020006) was conducted across 14 study centers, with enrollment beginning November 2009 and the study ending August 2012. Part A was a nonrandomized, intrapatient, dose escalation lead-in portion starting at 0.8 mg/kg (maximum 1.5 mg/kg) PCI-27483 administered b.i.d. by SC injection in patients concurrently receiving gemcitabine for 12 weeks; in part B, patients were randomized 1: 1 to receive the recommended phase 2 dose (RP2D, 1.2 mg/kg b.i.d.) of PCI-27483 combined with gemcitabine (the standard of care at time of study initiation) or gemcitabine alone. This dose was selected based upon attainment of the targeted pharmacodynamic effect (INR between 2.0 and 3.0) with an acceptable AE profile reported in part A. Gemcitabine was given intravenously at 1 g/m 2 once weekly for 3 weeks out of every 4 weeks, and PCI-27483 was self-administered SC b.i.d. continuously. Eligible patients included adults with metastatic ductal adenocarcinoma (mPC) of the pancreas diagnosed ≤4 months prior to enrollment or locally advanced ductal adenocarcinoma (LAPC) of the pancreas diagnosed ≤6 months prior to enrollment (part B). Patients with a history of disease progression during gemcitabine treatment or history of VTE were excluded.
The primary objective for part A was to evaluate safety and tolerability of PCI-27483 and to establish RP2D; the primary objective for part B was to compare safety and tolerability of PCI-27483-gemcitabine with gemcitabine alone in patients with mPC or LAPC. Power computations were not of primary interest, and sample size of the study was not based on safety endpoints but rather on considerations of various activity outcomes. Based on pharmacodynamic and safety profiles obtained from single doses in healthy volunteers and from preclinical studies, planned enrollment for part A was approximately 6 patients. In part B, 40 patients were planned to be randomized to either arm in a 1: 1 ratio based on considerations of various activity outcomes, including approximately 80% power at 1-sided significance level of 0.20 for progressionfree survival (PFS) and overall survival (OS) benefit.
Assessments
Safety data were collected from time of first dose until week 16 or 28 ± 2 days after last dose, whichever occurred last. Vital signs and Eastern Cooperative Oncology Group performance status (ECOG PS) were measured at screening and during selected study visits. Efficacy evaluations included PFS, OS, serum cancer antigen 19-9 measurements, objective tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and spiral computed tomography, at baseline and every 8 weeks. Arm comparisons were performed in part B. PFS and OS were analyzed by log-rank test; hazard ratios (HRs) were estimated by Cox regression, and overall response rates were compared using the CochranMantel-Haenszel χ 2 test. All tests were stratified by local advanced or metastatic disease.
Results
In part A, 8 patients enrolled and received PCI-27483-gemcitabine. In part B, 34 patients were randomized to receive either PCI-27483-gemcitabine (n = 18) or gemcitabine alone (n = 16); the study closed to accrual due to slow enrollment. Patient demographics and baseline characteristics were balanced for patients enrolled in part B (Table 1) , though differences in biomarkers were not clinically meaningful given the small numbers in each arm.
The overall safety profile of grade ≥3 AEs was similar in patients who received PCI-27483-gemcitabine versus gemcitabine. Nonetheless, serious AEs were higher in the PCI-27483-gemcitabine arm compared to gemcitabine (Table  2) . AEs leading to PCI-27483 dose modification occurred in 14/26 PCI-27483-treated patients; increased INR (31%) and prolonged prothrombin time (12%) were the only AEs occurring in more than 1 patient. Overall, the most common AEs leading to PCI-27483 discontinuation were gastrointestinal disorders, including gastrointestinal hemorrhage, and increased INR. AEs that occurred with a ≥20% difference in incidence between patients who received PCI-27483-gemcitabine versus gemcitabine primarily affected <6 pg/mL 6-10 pg/mL >10 pg/mL 1 (13) 4 (50) 0 10 (56) 4 (22) 3 (17) 4 ( Data are presented as median (range) or n (%). ECOG PS, Eastern Cooperative Oncology Group performance status; IL-8, interleukin-8; INR, international normalized ratio; serum CA 19-9, serum cancer antigen 19-9. a n = 17 for PCI-27483-gemcitabine. coagulation and hemoglobin parameters, including increased INR (46% vs. 0), injection site hematoma (38% vs. 0), and also included dizziness (23% vs. 0). The incidence of any-grade bleeding events was higher for PCI-27483-gemcitabine than gemcitabine (65% vs. 19%), with similar incidence of grade ≥3 bleeding events (15% vs. 13%). Overall, 9 patients treated with PCI-27483-gemcitabine received transfusions. One of 26 patients (4%) treated with PCI-27483-gemcitabine experienced VTE (grade 2), while 2/16 patients (13%) treated with gemcitabine experienced VTE (grade 2 and grade 4). 
Pharmacokinetics
Efficacy
The overall response rate was zero for part A, and for part B it was 11% for patients who received PCI-27483-gemcitabine and 6% for gemcitabine (odds ratio, 1.87; p = 0.612). In part B, median PFS was 3.7 months for patients who received PCI-27483-gemcitabine and 1.9 months for gemcitabine (Fig. 1a) , with a nonsignificant trend in favor of PCI-27483-gemcitabine (HR, 0.62; p = 0.307). The median OS was 5.7 months for patients who received PCI-27483-gemcitabine and 5.6 months for patients who received gemcitabine in part B (HR, 0.95; p = 0.898; Fig. 1b) . There was no significant difference in OS between PCI-27483-gemcitabine versus gemcitabine.
Discussion
This phase 2 study was designed to evaluate the safety of PCI-27483 in patients with mPC or LAPC receiving concurrent gemcitabine. Upregulated TF has been linked with tumor invasiveness and increased VTE [16, 17] . Since PCI-27483 inhibits FVIIa, which initiates the coagulation cascade after binding with TF [2] , it was hypothesized that PCI-27483 may reduce VTE complications and potentially increase survival in patients with APC.
Combination PCI-27483-gemcitabine was well tolerated and did not appear to affect the safety or tolerability of gemcitabine. Incidence of grade ≥3 severe bleeding in patients treated with PCI-27483-gemcitabine was comparable to that of gemcitabine, although low-grade bleeding was more common with PCI-27483-gemcitabine. There was a trend toward lower incidence of VTE with PCI-27483-gemcitabine versus gemcitabine.
In part B, INR values in patients treated with PCI-27483 were mostly within the targeted range: median INR increased from 1.1 at baseline to 2.0 within 2 hours post-first dose of PCI-27483-gemcitabine and to 2.7 at 2 hours post-dose C3D1. An increase in INR was observed solely in patients treated with PCI-27483-gemcitabine, consistent with the mechanism of action of PCI-27483.
There was a nonsignificant trend toward longer PFS in patients receiving PCI-27483-gemcitabine. There was no significant difference in OS between treatment groups. Even though significant clinical efficacy between PCI-27483-gemcitabine and gemcitabine was not reached, targeted inhibition of the coagulation cascade was achieved. While PCI-27483 will not be evaluated further in APC, this study demonstrates the potential for and hypothesis of targeted inhibition of the coagulation cascade for treatment of APC. 
